Medicare’s New Drug Price Mandate: Healthcare & Innovation Implications
June 23, 2025 at 12 pm ET
On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of drugs covered by the Medicare Drug Price Negotiation Program of the Inflation Reduction Act (IRA). Now there are a total of 25 drugs that are covered by the IRA’s requirement that the Department of Health and Human Services (HHS) pays only a “fair price” for selected drugs covered by Medicare Part D. The new prices are set to take effect on January 1, 2027. What implications does this have for patients and for drug research and development?
Join the discussion on the ‘fair price’ mandate and its impact on pharmaceutical innovation.
Featuring:
Lisa Ouellette, Deane F. Johnson Professor of Law at Stanford Law School
Dan Troy, Managing Director at the Berkeley Research Group
Brad Watts, Senior Vice President at the Global Innovation Policy Center, U.S. Chamber of Commerce
[Moderator] Adam Mossoff, Professor of Law at Antonin Scalia Law School, George Mason University
Panelists
Topic
The Federalist Society and Regulatory Transparency Project take no position on particular legal or public policy matters. All expressions of opinion are those of the speaker(s). To join the debate, please email us at [email protected].
